Literature DB >> 17098461

Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2.

Demetra Mavri-Damelin1, Simon Eaton, Leonard H Damelin, Myrddin Rees, Humphrey J F Hodgson, Clare Selden.   

Abstract

A possible cell source for a bio-artificial liver is the human hepatblastoma-derived cell line HepG2 as it confers many hepatocyte functions, however, the urea cycle is not maintained resulting in the lack of ammonia detoxification via this cycle. We investigated urea cycle activity in HepG2 cells at both a molecular and biochemical level to determine the causes for the lack of urea cycle expression, and subsequently addressed reinstatement of the cycle by gene transfer. Metabolic labelling studies showed that urea production from 15N-ammonium chloride was not detectable in HepG2 conditioned medium, nor could 14C-labelled urea cycle intermediates be detected. Gene expression data from HepG2 cells revealed that although expression of three urea cycle genes Carbamoyl Phosphate Synthase I, Arginosuccinate Synthetase and Arginosuccinate Lyase was evident, Ornithine Transcarbamylase and Arginase I expression were completely absent. These results were confirmed by Western blot for arginase I, where no protein was detected. Radiolabelled enzyme assays showed that Ornithine Transcarbamylase functional activity was missing but that Carbamoyl Phosphate Synthase I, Arginosuccinate Synthetase and Arginosuccinate Lyase were functionally expressed at levels comparable to cultured primary human hepatocytes. To restore the urea cycle, HepG2 cells were transfected with full length Ornithine Transcarbamylase and Arginase I cDNA constructs under a CMV promoter. Co-transfected HepG2 cells displayed complete urea cycle activity, producing both labelled urea and urea cycle intermediates. This strategy could provide a cell source capable of urea synthesis, and hence ammonia detoxificatory function, which would be useful in a bio-artificial liver.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098461     DOI: 10.1016/j.biocel.2006.10.007

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  18 in total

1.  Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Tianlu Chen; Guoxiang Xie; Xiaoying Wang; Jia Fan; Yunping Qiu; Xiaojiao Zheng; Xin Qi; Yu Cao; Mingming Su; Xiaoyan Wang; Lisa X Xu; Yun Yen; Ping Liu; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-04-25       Impact factor: 5.911

2.  Pivotal preclinical trial of the spheroid reservoir bioartificial liver.

Authors:  Jaime M Glorioso; Shennen A Mao; Brian Rodysill; Taufic Mounajjed; Walter K Kremers; Faysal Elgilani; Raymond D Hickey; Hakon Haugaa; Christopher F Rose; Bruce Amiot; Scott L Nyberg
Journal:  J Hepatol       Date:  2015-03-25       Impact factor: 25.083

3.  Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.

Authors:  Janice Cho; Joy C Y Chen; Jonas Paludo; Erin E Conboy; Brendan C Lanpher; Steven R Alberts; Thorvardur R Halfdanarson
Journal:  J Gastrointest Oncol       Date:  2019-06

4.  Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation.

Authors:  Saurabh Vig; Puneet Talwar; Kirandeep Kaur; Rohit Srivastava; Arvind K Srivastava; Malabika Datta
Journal:  Cell Cycle       Date:  2015-05-06       Impact factor: 4.534

5.  Arginase I mRNA therapy - a novel approach to rescue arginase 1 enzyme deficiency.

Authors:  Kirtika H Asrani; Lei Cheng; Christopher J Cheng; Romesh R Subramanian
Journal:  RNA Biol       Date:  2018-07-24       Impact factor: 4.652

6.  Gene expression profiling and network analysis reveals lipid and steroid metabolism to be the most favored by TNFalpha in HepG2 cells.

Authors:  Amit K Pandey; Neha Munjal; Malabika Datta
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

7.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

8.  Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver.

Authors:  Geir I Nedredal; Bruce P Amiot; Peter Nyberg; Jennifer Luebke-Wheeler; Joseph B Lillegard; Travis J McKenzie; Scott L Nyberg
Journal:  Biotechnol Bioeng       Date:  2009-12-01       Impact factor: 4.530

9.  The Microfluidic Environment Reveals a Hidden Role of Self-Organizing Extracellular Matrix in Hepatic Commitment and Organoid Formation of hiPSCs.

Authors:  Federica Michielin; Giovanni G Giobbe; Camilla Luni; Qianjiang Hu; Ida Maroni; Michael R Orford; Anna Manfredi; Lucio Di Filippo; Anna L David; Davide Cacchiarelli; Paolo De Coppi; Simon Eaton; Nicola Elvassore
Journal:  Cell Rep       Date:  2020-12-01       Impact factor: 9.423

10.  Bioengineering the liver: scale-up and cool chain delivery of the liver cell biomass for clinical targeting in a bioartificial liver support system.

Authors:  Eloy Erro; James Bundy; Isobel Massie; Sherri-Ann Chalmers; Aude Gautier; Spyridon Gerontas; Mike Hoare; Peter Sharratt; Sarah Choudhury; Marcin Lubowiecki; Ian Llewellyn; Cécile Legallais; Barry Fuller; Humphrey Hodgson; Clare Selden
Journal:  Biores Open Access       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.